UNSPSC 51401551: Sulazepam

This classification denotes an anxiolytic with the molecular formula C16H13ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NZ779Q5S0W, chemically known as 7-chloro-2,3-dihydro-1-methyl-5-phenyl-1,4-benzodiazepine-2-thione but generally known as sulazepam, which bears US NIH Compound Identifier 17931. European Medicines Agency schedules Sulazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10674MIG. The term SULAZEPAM is an International Non-Proprietary Name.

UNSPSC 51401551 Sulazepam is a Commodity code that does not map to the pharmaceutical procurement activity currently appearing in state and local opportunities. The recent solicitations tagged under this code—naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals—involve finished pharmaceutical products, medical devices, and pharmacy benefit management services, none of which correspond to sulazepam as a distinct pharmaceutical ingredient or category. The code shows little relevant recent activity aligned with its nominal scope.

The three recent opportunities on file span health agencies and cooperative purchasing vehicles: Seminole County, Florida issued an IFB for naloxone and safe drug deactivation systems (due July 26, 2023); the Texas Health and Human Services Commission released an RFI on direct-to-manufacturer prescription programs (due April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). The geographic spread includes Florida, Texas, and Minnesota, with MMCAP serving multiple states including Oregon. No award values or budget allocations are disclosed in the available materials. Vendors pursuing pharmaceutical procurement at the state and local level should track broader pharmaceutical Commodity codes rather than this code, and monitor cooperative purchasing RFPs issued by MMCAP and comparable multistate alliances where volume and geographic reach are substantial.